However, a recent study suggested that FAT1-mutated NSCLC exhibited a more durable clinical benefit and better objective response rate to anti-PD-L1 therapy [24], which is inconsistent with analysis in the current study. This evidence concerns the gene FAT1 and non-small cell lung carcinoma.